Keywords: Contrast Agents, Liver, chronic diseases, fibrosis, precision MRI
Motivation: Hepatic fibrosis can develop in patients with any type of chronic liver disease which increase the risk of death for an estimated 1–2% of the world’s population.
Goal(s): Our goal is to develop novel MRI contrast agents for liver diseases which enable us to detect the liver diseases at early stages.
Approach: We developed the novel MRI contrast agent for precision MRI. We achieved the molecular imaging on different animal models with liver diseases.
Results: Our results shows that our protein based MRI contrast agent can target the small lesions and fibrotic areas in the liver.
Impact: The Protein based contrast agent with specific targeting capabilities is able to stage the liver diseases accurately.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords